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The microRNA miR-155 is prominent in cancer biology. Among microRNAs that have been linked to cancer, it is the
most commonly overexpressed in malignancies (PNAS 109:20047-20052, 2012). Since its discovery, miR-155 has
been implicated in promoting cancers of the breast, lung, liver, and lymphatic system. As such, targeted therapies
may prove beneficial to cancer treatment. This review discusses the important role of miR-155 in oncogenesis. It
synthesizes information from ten recent papers on miR-155, and includes an analysis and discussion of its
association with cancer, interactions with other miRNAs, mechanisms of action, and the most promising available
treatment options.
Current debates in the field include the importance of miRNAs in general and their utility as targets in
preventing tumorigenesis (Blood 119:513-520, 2012). Most of the papers being reviewed here confirm the
role of miR-155 in oncogenesis (EMBO Mol Med 1:288-295, 2009). While there is some controversy
surrounding recent research that claims that miR-155 may display anti-oncogenic or pro-immunological
benefits (Cell Rep 2:1697–1709, 2012), most research seems to point to the importance of anti-miRs, with
anti-miR-155 in particular, for cancer therapy.
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MicroRNAs (miRNAs) are short (about 21 nucleotides
long) strands of non-coding RNA that regulate the ex-
pression of multiple genes [1]. They are important post-
transcriptional regulators of gene expression in plants,
metazoans, and mammals, and are predicted to control
the activity of 30% of all protein-coding genes [2]. MiRNAs
control cell functions by silencing genes or gene clusters
and may inhibit RNA translation by mRNA uncapping and
deadenylation, which lead to increased mRNA turnover
and decreased target gene expression [3].
Because of their wide variety of targets, miRNAs have
been found to affect numerous developmental processes
within cells including hematopoietic lineage differenti-
ation, immunity, inflammation, and tumorigenesis [4,5].
Those miRNAs that lead to tumorigenesis and cancer
are classed as oncomiRs. These oncomiRs are not only* Correspondence: gadareth.higgs@yale.edu
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distribution, and reproduction in any mediumtherapeutic targets, but also important biomarkers for
cancer detection and management [6].
Among the known oncomiRs, miR-155 stands out as
an important entity [7]. It is one of the most commonly
up-regulated miRNAs in solid and hematological malig-
nancies [8], and has been linked to the development of
leukemia, breast, lung, and stomach tumors [9]. As such,
it is an important target for diagnosis, prognosis [10],
and therapy. While experimental evidence has shown
that miR-155 is over-expressed in malignant tumors, the
specific mechanism of action of miR-155 was unknown
until recently.
MiR-155 is produced from the processing of the B-
Cell Integration Cluster (BIC), which is a non-coding
transcript expressed in activated B cells, T cells, mono-
cytes and macrophages [11,12]. The BIC gene is acti-
vated by promoter insertion at a retroviral integration
site on chromosome 21q21 in B cell lymphomas induced
by avian leukosis virus. Knockouts of miR-155 show de-
fects in hematopoietic development [13].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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What are the physiologic and oncogenic functions of
miR-155?
Cancer is marked by six hallmarks:
1. Maintaining proliferative signaling
2. Evading growth inhibitors
3. Resisting cell death
4. Enabling replicative immortality
5. Inducing angiogenesis
6. Activating invasion and metastasis
As a prominent oncomir, miR-155 plays a role in many
of the above oncogenic processes. It down-regulates
BCL6 (B-cell lymphoma 6) protein [8], which is an evo-
lutionarily conserved zinc finger transcription factor that
contains an N-terminal POZ/BTB domain. As BCL6 has
been shown to modulate the STAT-dependent Interleu-
kin 4 (IL-4) responses of B cells, miR-155 acts to in-
crease B cell functioning. Also, since BCL6 interacts
with several co-repressor complexes to inhibit transcrip-
tion, and its gene is frequently trans-located and hyper-
mutated in diffuse large B cell lymphoma (DLBCL),
miR-155 acts to enhance transcription and contribute to
the pathogenesis of DLBCL. Reduction of BCL6 then leads
to up-regulation of known BCL6 targets such as inhibitor
of differentiation (Id2), Interleukin-6 (IL6), cMyc, Cyclin
D1, and Mip1α/Ccl3, all of which promote cell survival
and proliferation [8].
MiR-155 also upregulates Mxd1/Mad1, a network of
basic helix-loop-helix leucine zipper transcription factors
which mediate cellular proliferation, differentiation, and
apoptosis, through regulating BCL6. In this way, MiR-
155 leads to the resistance of cell death and enables rep-
licative immortality.
HDAC4 (histone deacetylase 4), a co-repressor partner
of BCL6, is a direct target of miR-155. As histones play a
critical role in transcriptional regulation, cell cycle progres-
sion, and developmental events, HDAC4 alters chromo-
some structure and affects transcription factor access to
DNA. It does not bind DNA directly, but attaches through
the transcription factors MEF2C and MEF2D. Analysis of
DLBCL patient data showed that miR-155 expression is in-
versely correlated with Bcl6 and HDAC4 [8]. Additionally,
miR-155 was upregulated in Hodgkin, primary mediastinal
B-cell lymphoma, and DLBCL [8].
Mir-155 was also shown to down-regulate HGAL by
binding to its 3′ UTR, leading to decreased RhoA activa-
tion and increased spontaneous and chemoattractant-
induced lymphoma cell motility [14]. MiR-155 directly
increased TNF-α levels by augmenting transcript stabil-
ity through binding of its 3′ UTR. MiR-155 also targets
gene transcripts coding for proteins that are known to
be TNF-α translation repressors [4], and evades growthinhibitors by targeting SH2-containing inositol phosphat-
ase (SHIP1), a negative regulator of myeloid cell prolifera-
tion and survival [15].
Hexokinase 2 (hk2) is up-regulated by miR-155 through
two distinct mechanisms. Firstly, miR-155 promotes hk2
transcription by activation of signal transducer and activa-
tor of transcription 3 (STAT3), a transcriptional activator
for hk2. Secondly, by targeting C/EBPβ (a transcriptional
activator for mir-143), miR-155 represses mir-143, a nega-
tive regulator of hk2, thus resulting in up-regulation of
hk2 expression at the post-transcriptional level [16].
The suppression of miR-155 inhibited cell proliferation
and migratory activity and induced apoptosis in renal
cancer cells. The suppressor gene suppressor of cytokine
signaling (SOCS-1) and BACH1 were predicted as poten-
tial target genes by bioinformatics analysis. The suppres-
sion of miR-155 inhibited BACH1 protein expression.
Therefore, it was determined that miR-155 may function
as an oncogene by targeting BACH1 [17].
In the Leukemia paper by Forrest et al., Mir155 was
found to induce G2 arrest [18]. Ectopic miR155 expres-
sion in mice B cells induced pre-B cell proliferation
followed by high-grade lymphoma/leukemia [8].
MiR-155 (along with miR-125b) was also a contributor
to BCL2 repression and proliferation in response to CD40
ligand (CD154) in human leukemic B-cells [19]. MiR-155
also targeted casein kinase 1α (CK1α), which enhanced
β-catenin signaling and cyclin D1 expression, thereby
promoting tumor cell growth [3]. In the Willimott and
Wagner paper, it was shown that MiR-155 repressed
BCL2 mRNA. This required CD154, which resists cell
death.
It has also been shown that miR-155 is epigenetically
repressed by BRCA1 (breast cancer type 1 susceptibility
protein). This occurs via an association with HDAC2,
which deacetylates H2A and H3 on the miR-155 pro-
moter [20], and is shown in Figure 1 below.
What is miR-155′s association with cancer?
In a paper by Pedersen et al., miR-155 was shown to be
an oncomiR whose expression in B cells alone triggers
malignant transformations [21]. The authors studied
the effect of miR-155 in diffuse large B-cell lymphoma
(DLBCL) and identified the SH2 domain containing
inositol-5-phosphatase (SHIP1) as a target of miR-155.
SHIP1 is a hematopoietic cell protein whose movement,
from cytosol to plasma membrane, is mediated by tyrosine
phosphorylation.
It was demonstrated that DLBCL cells showed elevated
levels of miR-155 and diminished levels of SHIP1 [21].
This was believed to have been the result of autocrine
stimulation by cytokine TNF-α. The authors showed that
the administration of anti-TNF-α regimen with eternacept





















Figure 1 Normal BRCA1 represses miR-155 expression via its association with HDAC2 [20].
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decreased along with tumor size, showing that cytokine-
regulated miRNAs, such as miR-155, are a critical link be-
tween inflammation and cancer. This paper was important
because anti-TNF-α therapy for DLBCL was both novel
and easily accessible. As DLBCL accounts for about 40%
of adult non-Hodgkin lymphomas, this research has im-
portant applications for cancer treatment.
While there is overwhelming evidence that miR-155
expression is linked to lymphatic cancers [8,14,15,21-23],
in their 2012 paper, Pingyu Zhang and fellow researchers
at The University of Texas MD Anderson Cancer Center
showed that miR-155 also plays a role in liposarcoma [3].
In this study, the authors studied the expression profile
signature of 35 miRNAs and found that miR-155 was the
most overexpressed. They found that this miRNA was in-
tegral in the growth of dedifferentiated liposarcoma cell
lines and that miR-155 knockdowns induced G1S cell-
cycle arrest, inhibited tumor cell growth, and had de-
creased colonies. The researchers also determined that
miR-155 targeted casein kinase 1-α (CK1-α), enhancing
Beta-catenin signaling and cyclin D1 expression, thereby
promoting tumor cell growth.
This study was significant because it showed that miR-
155 has a role in mesenchymal solid malignancy. Previ-
ously, miR-155 had been implicated in the promotion of
hematologic and epithelial cancers.
Much of the current research in the field has impli-
cated miR-155 in promoting oncogenesis. However, in
their recent Blood paper, Zonari et al. studied the anti-oncogenic effects of miR-155 [24]. They discovered that
miR-155 knockdown in myeloid cells facilitated breast
cancer development in mice. It was shown that miR-155
was required by tumor-associated macrophages (TAMs)
for anti-tumoral activity. They determined that the miR-
155 knockdown promoted tumor growth by impairing
classical activation of tumor-associated macrophages
(TAMs). This, in turn, led to a reduction in CD11c+
TAMs, reduced expression of activation markers, and a
skewing of tumor immune cells to an M2/Th2 response.
Their research was done in MMTV-PyMT mice, which
is a mouse model that closely mimics tumor-host interac-
tions seen in humans. While this research could be applic-
able to Homo sapiens, the authors themselves noted that
results generated in mice might not apply to humans [24].
Therefore, more research must be done in this arena be-
fore one can translate these results into clinical trials.
The preceding papers show that miR-155 plays an
integral role in lymphatic cancer, liposarcoma and breast
cancer by affecting different targets. Table 1 below sum-
marizes many of the known important targets of miR-155.
In propagating lymphatic cancer, miR-155 is upregulated
by the cytokine TNF-α, and targets SHIP1, an important
protein for myeloid cell proliferation and survival. In
liposarcoma, miR-155 targets CK1-α to enhance Beta-
catenin signaling and cyclin D1 expression and promote
tumor cell growth. In breast cancer, miR-155 associates
with TAMs, which prevent tumor growth, and therefore
seems to prevent breast cancer in mice. The table also
shows that miR-155 targets molecules that play a role in
Table 1 MiR-155 target genes & associations
MiR-155 target Association
SHIP & C/EBP-Beta B-cell malignancies [3]
TP53INP1 Pancreatic Cancer [3]
FOXO3 Secondary Acute Leukemia (MLL) [3]
RHOA Breast Cancer [3]
MSH2 Colon Cancer [3]
MSH6 Colon Cancer [3]
MLH1 Colon Cancer [3]







BACH1 Renal Cancer [17]
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cer. In each study, miR-155 interacts with proteins and
other molecules in order to affect the progression to
cancer. However, miR-155 also associates with other
miRNAs, and in the next section, these associations will
be explored.
Interaction with other miRNAs
MiR-155 has been shown to interact with other miRNAs
in the regulation of cancer [16]. In their 2012 paper,
Jiang and fellow researchers discovered a novel miR-
155/miR-143 cascade that controlled glycolysis in breast
cancer cells. They found that miR-155 was induced by
inflammation, and it mediated cytokines, which promoted
glycolysis. MiR-155 was found to up-regulate HK2 by acti-
vating Signal Transducer and Activator of Transcription
3 (STAT3), and targeting C/EBP-β (CCAAT/enhancer-
binding protein beta: a transcription activator for miR-143).
Therefore, upregulation of miR-155 led to miR-143 re-
pression and HK2 up-regulation. Knockdowns of miR-155
reduced the effect that inflammatory cytokines had on gly-
colysis in breast cancer cells. MiR-155 was also found to
promote pro-tumorigenic inflammatory STAT3 signaling
by targeting (Suppressor of Cytokine Signaling 1) SOCS1,
a repressor of Janus Kinase (JAK)/STAT signaling.
In summary, inflammation promoted glucose metabol-
ism in cancer cells through miR-155-SOCS1-STAT3-HK2
and miR-155-C/EBPb-miR-143-HK2 cascades [16]. As
miR-155 is upregulated after various inflammation stimuli,
it forms an integral link between inflammation and cancer,
as shown in Figure 2 below.
In their 2010 paper, Willimott and Wagner studied how
miR-155 and miR-125b contributed to BCL2 repressionand malignant cell proliferation [19]. They found that
miR-155 and miR-125b repress BCL2 translation and me-
diate the proliferative response to CD40 ligand (CD154).
CD40 signaling, in turn, promotes proliferation and res-
cues B-cells from apoptosis by inducing BCL2L1 and
BCL2A1, while repressing BCL2. As CD154 drives mature
B-cell malignancy proliferation, counteracting the effects
of miRNAs induced by CD154 may have therapeutic
benefits.
The addition of anti-miR-155 and anti-miR-125b
prevented CD154-mediated repression of BCL2 and
reduced CD154-mediated proliferation in the MEC1
B-cell line. CD-154 was found to increase miR-155 asso-
ciation with polysomes, while BCL2 was determined to be
involved in chromosomal translocations in follicular
lymphoma. MiR-155 was the most abundant miRNA
under basal conditions [19]. This paper was important as
it investigated the effect that miR-155 has on the import-
ant oncogene BCL2.
The preceding papers show that miR-155 interacts
with miR-143 and miR-125b to promote malignant
breast cell proliferation through the upregulation of in-
flammatory cytokine HK2 and tumor necrotic factor
CD40. So far, we have seen how miR-155 causes cancer
in most cases, prevents it in others, and associates with
other microRNAs. The following section focuses on
other important mechanisms of miR-155 action.
Mechanisms of miR-155 action
In their 2009 Nature Leukemia paper, Forrest et al. stud-
ied how the induction of miR-155 promotes monocytic
differentiation [18]. Their goal was to determine miRNAs
that are regulated by phorbol myristate acetate (PMA),
which is used to overcome a block in terminal differenti-
ation of the myeloid lineage and progenitor state prolifera-
tion associated with AML in THP-1 cells. Along with
miR-222, miR-424, and miR-503, miR-155 was the top
PMA-induced miRNA, and it caused cell cycle arrest and
partial differentiation when overexpressed.
This research showed that miR-155 plays a role in
apoptosis by targeting anti-apoptotic factors such as
RPS6KA3, SGK3, RHEB, and KRAS. MiR-155 was also
determined to partially promote monocytic differenti-
ation with selective depletion of myeloid and erythroid
hematopoietic stem cell populations occurring in prefer-
ence for B-cell proliferation. After 96-hour PMA-induced
differentiation, THP-1 acute monolytic leukemia cells
showed a 3-fold change in miR-155 expression through
microRNA array analysis, and a 1.3-fold change in small
RNA sequencing [18]. The data came from the FANTOM4
(Functional ANnoTation Of Mammals) project, which uses
deep sequencing, bioinformatics predictions, microarrays,
and siRNA perturbations to map a network of mammalian












Figure 2 The interplay of MiR-155 in inflammation and the Warburg effect of cancer [16].
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sought insight into miR-155-induced leukemogenesis in
Eμ-miR-155 transgenic mice. They did this through
genome-wide transcriptome analysis of naïve B cells
and target studies [8].
It was found that miR-155/BIC expression was nega-
tively correlated with histone deacetylase 4 (HDAC4)
and the transcriptional repressor and proto-oncogene,
BCL6, in DLBCL patients. BCL-6 was downregulated
in Eμ-miR-155 mice, while loss of miR-155 resulted
in impaired immunity. This was due to defective T-
cell-mediated immune response. BCL-6 was found to
target the inhibitor of DNA-binding ID2, IL-6, cMyc,
cyclin D1 and MiP1alpha/cd3, which all promote cell
survival and proliferation. MiR-155 was determined to
regulate BCL-6 through Mxd1/Mad1 upregulation. It
also upregulated survival and proliferation genes (as no-
ticed in miR-155-induced leukemias) and disrupted the
BCL6 transcriptional machinery. Furthermore, miR-155
directly targeted HDAC4, a corepressor partner of BCL6.
Ectopic expression of HDAC4 in human-activated DLBCLcells resulted in reduced miR-155-induced proliferation,
clonogenic potential, and increased apoptosis. Tables 2
and 3 below show some of the pathways regulated by
miR-155.
The previous studies show that miR-155 plays an inte-
gral role in numerous pathways. Specifically, miR-155
was shown to enhance AHR signaling, glutathione me-
tabolism, mitosis, communication between innate and
adaptive immune cells, and pattern recognition recep-
tors. Meanwhile, miR-155 reduces IRF activation, and
signaling for SAPK/JNK, toll-like receptors, ATM, ERK/
MAPK, and B-cell receptors. Over the past few years, we
have learned much about miR-155, its many mecha-
nisms of action, and its interactions with other miRNAs.
Combining this information with what we know about
its role in cancer, we have also come up with promising
new treatment options for patients.
Anti-miR-155 treatment options
Traditional cancer therapy involves chemotherapy and
radiation, which can lead to iatrogenic issues such as hair
Table 2 Pathways up-regulated in Eμ-miR-155 mice naïve
B cells
Pathways Molecules
AHR Signaling MGST1, CCNE2, NFIX, TFDP1,
GSTM5, NQO2, POLA1, CDK6,
CCND1, GSTO1, CHEK1, MYC, TGM2,
CCNA2, CCND3, ALDH1A1, MGST2,
E2F1, DHFR, ESR1, AHR [8]
Glutathione Metabolism GSR, MGST1, MGST2, GSTM5, G6PD,
IDH2, GCLM, GLRX, ANPEP, GSTO1,
RNPEP, IDH1 [8]
Mitotic Roles of Polio-like
Kinase
KIF23, PLK4, ESPL1, CDC20, PRC1,
CCNB2, PLK1, CDK1, KIF11 [8]
Communication between innate
and adaptive immune cells
TNFSF13, IL15, TLR7, FCER1G, Tlr13,
IGHG1, CCL5, TLR3, CD8A, CCL9 [8]
Role of pattern recognition
receptors in recognition of
bacteria and viruses
IFIH1, CLEC7A, OAS1, C3, PIK3R6,
TLR7, CCL5, EIF2AK2, TLR3, RNASEL
[8]
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some naturally occurring compounds such as curcumin,
genistein, tea polyphenols, resveratrol, and sulforaphane
seem to have anti-cancer properties [25-27]. In their
groundbreaking Carcinogenesis paper, Tili et al. investigated
the effect of resveratrol (trans-3,4′,5-trihydroxystilbene), a
dietary polyphenolic, non-flavonoid antioxidant derived
from grapes and berries, in inhibiting cancer [9]. They
found that resveratrol impaired the lipopolysaccharide-
induced upregulation of miR-155 in a way that depends on
miR-663. Resveratrol was found to upregulate miR-663,
which was found to decrease endogenous AP-1 activity and
target jun-B and jun-D transcripts. Jun-B regulates gene ac-
tivity following the primary growth factor response, and
Jun-D protects cells from p53-dependent senescence and
apoptosis.
Given miR-155′s role in oncogenesis, it would cer-
tainly be a suitable target for anti-miRs. However, free-
floating anti-miRs are unstable in the plasma, must be
efficiently delivered, and must overcome such obstacles
as nucleases, non-specific tissue uptake, and renal clear-
ance [28].Table 3 Pathways down-regulated in Eμ-miR-155 mice
naïve B cells
Pathways Molecules
SAPK/JNK signaling GADD45A, DUSP4, MAP4K4, MAPK12,
ATF2 [8]
Activation of IRF by cytosolic
pattern recognition receptors
IKBKB, STAT2, MAPK12, ATF2 [8]
Toll-like receptor signaling IKBKB, MAP4K4, MAPK12 [8]
ATM signaling GADD45A, MAPK12, ATF2 [8]
ERK/MAPK signaling ETS2, DUSP4, RPS6KA5, RAPGEF4,
ATF2 [8]
B-cell receptor signaling IKBKB, MAPK12, BCL6, ATF2 [8]Recently, nanoparticle-based therapy has been shown
to be effective against miR-155-dependent lymphoma in
mice [15]. In research conducted at Yale, miR-155
overexpression in lymphoid tissues was shown to result
in disseminated lymphoma with a clonal, transplantable
pre-B-cell population of neoplastic lymphocytes. By con-
trast, miR-155 withdrawal by doxycycline resulted in
regression of lymphadenopathy via apoptosis of malig-
nant lymphocytes. When antisense peptide nucleic acids
were delivered via unique polymer nanoparticles, miR-
155 was inhibited and the growth of pre-B-cell tumors
was slowed in vivo.
This research was important for two main reasons.
Firstly, it confirmed that some lymphomas are miR-155
dependent. Secondly, it presented the most effective way
to reverse the effects of miR-155 tumorigenicity in vivo,
by nanoparticle delivery. This research was groundbreak-
ing, as it paved the way for additional research with
miR-155 and nanoparticles.
One such study took place at Ohio State University,
where Zhang and fellow researchers used lactosylated
gramicidin-containing lipid nanoparticles (Lac-GLN) to
effectively deliver anti-miR-155 to hepatocellular carcinoma
(HCC) cells [28]. The Lac-GLN formulation contained N-
lactobionyl-dioleoyl phosphatidylethanolamine (Lac-DOPE)
and an antibiotic peptide gramicidin A. Lac-DOPE is a lig-
and for the asialoglycoprotein receptor (ASGR).
While miR-155 expression was not affected, miR-155
target gene expression levels were upregulated in a dose-
dependent fashion. It is believed that the delivery of
anti-miR-155 blocked miR-155 function without facili-
tating its degradation. Low affinity binding of antisense
oligonucleotide and its miRNA were determined to pro-
mote miRNA degradation, while high affinity binding re-
pressed miRNA function [28].
This paper was among the first to report on a targeted
lipid-based peptide system for anti-miRNA hepatic deliv-
ery [28]. The efficacy of this method was evidenced by
the up-regulation of target genes that are repressed by
miR-155, and is an area of follow-up study. Nevertheless,
such research serves as a watershed in translating our
knowledge about miR-155 into effective cancer therapy.
Nanoparticle vehicles for anti-miR-155, particularly those
that are lipid-based, hold promise for use in orthodox
medicine, while resveratrol, and other naturally occurring
agents [25-27], may be used to complement this in home-
based or alternative treatment.
Conclusions
This review outlines the role of miR-155 in oncogenesis.
It targets numerous molecules in key signaling pathways
such as glutathione metabolism, SAPK/JNK, TLR, ERK/
MAPK, and B-cell receptor signaling. Because of its role
in signaling pathways, miR-155 is a key contributor to
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the lymphatic system.
Some novel concepts that arose from the analysis of
these papers were that miR-155 is not only a promoter
of many cancers, but may act to prevent cancer in trans-
genic mice by promoting proper immune function. This
finding conflicted what is generally known about miR-
155 and may be attributable to the fact that the study
was done in transgenic mice. Nevertheless this points
to a need for more rigorous and applicable studies in
humans, and to the vast effects of miR-155 on the
immune system [29].
MiR-155 was also implicated in promoting apoptosis
by targeting anti-apoptotic factors, and was seen to
counteract miRNAs such as miR-663 and miR-143, and
works along with miRNAs such as miR-125b and miR-
146 [23]. Additionally, miR-155 targets important onco-
genes such as BCL2, which regulates apoptosis, and BCL6,
which represses transcription. It also counters kinases
such as HK2, which phosphorylates glucose, thereby com-
mitting it to the glycolytic pathway. A recurring theme in
current research is that miR-155 represses SHIP1, which
serves an integral role in myeloid cell proliferation and
survival. Cancer cells are notorious for their ability to
evade apoptosis, and increase transcription and glucose
metabolism [30,31]. With its combined role in preventing
apoptosis, encouraging transcription, and blocking the
phosphorylation of glucose, miR-155 is an obvious pro-
moter of cancers, from lymphomas to mesenchymal ma-
lignancies such as liposarcoma.
This review outlined the emergence of novel treatment
options, ranging from easily accessible naturopathic
remedies such as resveratrol, to anti-TNF-α, and lipid
nanoparticles. These new therapies hold promise for
safer, more effective delivery cancer treatment in miR-
155-dependent malignancies. Given the success of lipid
nanoparticle delivery of anti-miR-155 in lymphoma and
hepatocellular carcinoma cells (HCC), such delivery
should be extended to other common sites of miR-155-
dependent cancer, such as the breast and lungs. In trans-
lating treatment into clinics, the liver may be an easier
target than most; it is a centralized organ through which
all blood is filtered. The lymphatic system, which is the
most common occurrence of cancers, may pose much
more difficulty for targeting vectors, as it is decentralized.
Future research in this arena should be focused on im-
proving the delivery of anti-oncomiRs to various tumor
sites and on determining the effect of miR-155 in human
tumors. Up to 25% of all cancers are due to chronic in-
flammation [32,33], while tumor metastasis is respon-
sible for 90% of all cancer deaths [8]. As miR-155 has
been linked to the development of lung and stomach tu-
mors, agents that effectively block miR-155 will have in-
credible utility in cancer therapy.Abbreviations
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proto-oncogene; KIF11: Kinesin family member 11; KIF23: Kinesin family
member 23; KRAS: Kirsten rat sarcoma viral oncogene homolog; Lac-DOPE:
N-lactobionyl-dioleoyl phosphatidylethanolamine; Lac-GLN: Lactosylated
gramicidin-containing lipid nanoparticles; MAP4K4: Mitogen-activated protein
kinase kinase kinase kinase 4; MAPK12: Mitogen-activated protein kinase 12;
MGST1: Microsomal glutathione S-transferase 1; MGST2: Microsomal glutathione
S-transferase 2; MiP1-alpha: Macrophage inflammatory protein alpha; miR-
155: microRNA-155; miRNA: microRNA; MLH1: MutL homolog 1; MMTV-
PyMT: Mouse mammary tumor virus-polyoma middle T (antigen); MSH2/
6: MutS protein homolog 2/6; MYC: V-myc myelocytomatosis viral oncogene
homolog (avian); NFIX: Nuclear factor I/X; NQO2: NAD(P)H dehydrogenase,
quinone 2; OAS1: 2′-5′-oligoadenylate synthetase 1; oncomiR: Oncogenic
microRNA; PIK3R6: Phosphoinositide-3-kinase, regulatory subunit 1; PLK1:
Polio-like kinase 1; PLK4: Polo-like kinase 4; PMA: Phorbol myristate acetate;
POLA1: Polymerase (DNA directed) alpha 1; PRC1: Protein regulator of
cytokinesis 1; RAPGEF4: Rap guanine nucleotide exchange factor 4; RHEB:
Ras homolog enriched in brain; RHOA: Ras homolog gene family, member A;
RNASEL: Ribonuclease L; RNPEP: Arginyl aminopeptidase (aminopeptidase B);
RPS6KA3: Ribosomal protein S6 kinase, 90 kDa, polypeptide 3; SAPK/
JNK: Mitogen-activated protein kinase 9, JUN N-terminal kinase; SGK3:
Serum/glucocorticoid regulated kinase family, member 3; SHIP1: SH2
domain containing inositol-5-phosphatase; siRNA: Small interfering RNA;
SOCS1: Suppressor of cytokine signaling 1; STAT2: Signal transducer and
activator of transcription 2; STAT3: Signal Transducer & Activator of Transcription
3; TAM: Tumor-associated macrophage; TFDP1: Transcription factor dimerization
partner 1; TGM2: Transglutaminase 2; THP-1: Tamm-Horsfall protein 1; TLR7:
Toll-like receptor 7; TNF: Tumor necrotic factor; TNFSF13: Tumor necrosis factor
(ligand) superfamily, member 13; TP53INP1: Tumor protein 53-inducible nuclear
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